​

Enveric Biosciences Stock (NASDAQ:ENVB)

RevenueOwnershipFinancialsChart
Enveric Biosciences by TradingView

Previous Close

$4.15

52W Range

$3.88 - $43.80

50D Avg

$5.23

200D Avg

$7.94

Market Cap

$46.27M

Avg Vol (3M)

$34.98K

Beta

0.47

Div Yield

-

ENVB Company Profile

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

7

IPO Date

May 04, 2015

Website

ENVB Performance

ENVB Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-16.45M$-27.42M$-64.62M
Net Income$-17.46M$-18.47M$-48.98M
EBITDA$-17.14M$-19.53M$-26.39M
Basic EPS$-808.63K$-12.77$-103.69
Diluted EPS$-808.63K$-12.77$-103.69

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
HEPAHepion Pharmaceuticals, Inc.
OCEAOcean Biomedical, Inc.
ELEVElevation Oncology, Inc.
ZURAZura Bio Limited